Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sutro Biopharma, Inc. STRO
$5.47
+$0.01 (0.09%)
На 18:01, 12 мая 2023
+293.05%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
332259288.00000000
-
week52high
8.72
-
week52low
3.33
-
Revenue
67772000
-
P/E TTM
-2
-
Beta
0.88789500
-
EPS
-2.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 мар 2023 г. в 20:30
Описание компании
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 23 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 мая 2022 г. |
| Berenberg | Buy | 17 ноя 2021 г. | |
| HC Wainwright & Co. | Buy | 18 июн 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 09 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 10 янв 2023 г. |
| Truist Securities | Buy | Buy | 13 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| NEWELL WILLIAM J | D | 13750 | 13750 | 27 янв 2023 г. |
| NEWELL WILLIAM J | D | 132187 | 5600 | 27 янв 2023 г. |
| NEWELL WILLIAM J | A | 137787 | 13750 | 27 янв 2023 г. |
| Hallam Trevor | D | 5250 | 5250 | 27 янв 2023 г. |
| Hallam Trevor | D | 83381 | 2140 | 27 янв 2023 г. |
| Hallam Trevor | A | 85521 | 5250 | 27 янв 2023 г. |
| FITZPATRICK LINDA A | D | 8250 | 8250 | 27 янв 2023 г. |
| FITZPATRICK LINDA A | D | 41210 | 3364 | 27 янв 2023 г. |
| FITZPATRICK LINDA A | A | 44574 | 8250 | 27 янв 2023 г. |
| Vasquez Nicki | D | 2500 | 2500 | 27 янв 2023 г. |
Новостная лента
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
GlobeNewsWire
08 мая 2023 г. в 08:00
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
Zacks Investment Research
04 мая 2023 г. в 05:21
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting
Seeking Alpha
11 апр 2023 г. в 13:17
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the molecule, I see little traction here.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
30 мар 2023 г. в 20:01
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
GlobeNewsWire
01 мар 2023 г. в 08:00
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA.